All In MedTech

FDA Clearance Tracker · P150048-S060

Edwards Pericardial Aortic Bioprosthesis and INSPIRIS RESILIA Aortic Valve

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Dec 29, 2022 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Dec 29, 2022

Approved

Time to decision

328 days

Received Feb 4, 2022. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P150048-S060
Device name
Edwards Pericardial Aortic Bioprosthesis and INSPIRIS RESILIA Aortic Valve
Applicant location
Irvine, CA
Received
Feb 4, 2022
Decided
Dec 29, 2022
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Location Change - Manufacturer/Sterilizer/Packager/Supplier
Original approval
P150048

Device type

Device class
Class III

Every decision under product code LWR

FDA's approval statement

As written in FDA's record.

Approval for a manufacturing site located at 35 Changi North Crescent, Changi, Singapore, 499641 for RESILIA/GLX processing and final packaging of the INSPIRIS RESILIA Aortic Valves, as well as an alternate ethylene oxide sterilization site at Sterile Services Singapore, 47 Jaran Buroh Unit #01-01, Singapore South West, Singapore 619491.

Source documents

Other decisions for Edwards Lifesciences, LLC

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.